These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20068343)

  • 21. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
    Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kudo M; Kim KI; Taniguchi M; Imoto S; Mita K; Hayashi Y; Shoji I; El-Shamy A; Hotta H
    Intervirology; 2010; 53(1):49-54. PubMed ID: 20068341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response.
    Barut S; Günal O; Erkorkmaz U
    Scand J Infect Dis; 2012 Oct; 44(10):761-5. PubMed ID: 22681186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.
    Ueda T; Chung H; Kudo M; Ishikawa E; Hayaishi S; Tatsumi C; Inoue T; Yada N; Hagiwara S; Minami Y; Ueshima K
    Intervirology; 2010; 53(1):55-9. PubMed ID: 20068342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
    Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
    Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin.
    Marino N; Blanc PL; Blè C; Pierotti P; Mazzotta F
    J Biol Regul Homeost Agents; 2003; 17(2):205-6. PubMed ID: 14518725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
    Saito T; Sugimoto M; Igarashi K; Saito K; Shao L; Katsumi T; Tomita K; Sato C; Okumoto K; Nishise Y; Watanabe H; Tomita M; Ueno Y; Soga T
    Metabolism; 2013 Nov; 62(11):1577-86. PubMed ID: 23953890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
    van Leusen R; Adang RP; de Vries RA; Cnossen TT; Konings CJ; Schalm SW; Tan AC
    Nephrol Dial Transplant; 2008 Feb; 23(2):721-5. PubMed ID: 18042614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.
    Ferrara F; Ventura P; Vegetti A; Guido M; Abbati G; Corradini E; Fattovich G; Ferrari C; Tagliazucchi M; Carbonieri A; Orlandini A; Fagiuoli S; Boninsegna S; Minola E; Rizzo G; Belussi F; Felder M; Massari M; Pozzato G; Bonetto S; Rovere P; Sardini C; Borghi A; Zeneroli ML; Toniutto P; Rossi E; Pietrangelo A
    Am J Gastroenterol; 2009 Mar; 104(3):605-16. PubMed ID: 19209167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.
    Hui CK; Monto A; Belaye T; Lau E; Wright TL
    Gut; 2003 Nov; 52(11):1644-8. PubMed ID: 14570736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
    Harada N; Hiramatsu N; Oze T; Yamada R; Kurokawa M; Miyazaki M; Yakushijin T; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Gastroenterol; 2013 Apr; 48(4):535-43. PubMed ID: 22976932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?
    Turbide C; Soulellis C; Deschênes M; Hilzenrat N
    Can J Gastroenterol; 2008 Feb; 22(2):149-52. PubMed ID: 18299740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.